Yoshindo Bags Biocon Biosimilars Rights In First Post-Lupin Deal
Yoshindo To Market Biocon’s Ustekinumab And Denosumab In Japan Once Approved
Yoshindo has gained exclusive Japanese commercialization rights to Biocon Biologic’s ustekinumab and denosumab candidates in a new deal. It comes a month after Yoshindo saw former partner Lupin take their own denosumab project elsewhere.
